Global Blood Therapeutics (GBT) Confirms FDA Approves Oxbryta for SCD
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day streak of losses despite Middle East clashes
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Google escapes ad tech breakup in third Big Tech antitrust loss for US
FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
November 25, 2019 4:04 PM ESTFirst and only FDA-approved sickle hemoglobin polymerization inhibitor, a new class of therapy
Oxbryta broadly indicated for the treatment of sickle cell disease in adults and children 12 years of age and older1
Approval comes three months ahead of FDAs priority review action date,
allowing for quicker patient access to Oxbryta
GBT to host conference call today, November 25, at 4:30 p.m. ET/1:30 p.m. PT
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Â Global Blood Therapeutics,... More
